Patents by Inventor Jeffrey A. Dodge

Jeffrey A. Dodge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190024838
    Abstract: A composite article has an increased peel strength and includes a first layer including a low surface energy polymer. The composite article also includes a poly(meth)acrylate layer, an epoxide layer, and a polyurethane elastomer layer. The poly(meth)acrylate layer is disposed on and in direct contact with the first layer. Moreover, the poly(meth)acrylate layer includes a poly(meth)acrylate that includes the reaction product of at least one (meth)acrylate that is polymerized in the presence of an or -ganoborane initiator. The epoxide layer is disposed on and in direct contact with the poly(meth)acrylate layer. The polyurethane elastomer layer is disposed on and in direct contact with the epoxide layer. The composite article has a 90° peel strength of at least 50 pli measured using ASTM D6862.
    Type: Application
    Filed: January 13, 2017
    Publication date: January 24, 2019
    Inventors: Jeffrey A. Dodge, Charles E. Jones
  • Publication number: 20190024839
    Abstract: A composite article includes a low surface energy polymer layer, a poly(meth)acrylate layer, an epoxide layer, and a hydrolytically resistant layer. The poly(meth)acrylate layer is disposed on and in direct contact with the low surface energy polymer layer and includes the reaction product of at least one acrylate that is polymerized in the presence of an organoborane initiator, such that the poly(meth)acrylate includes boron. The epoxide layer is disposed on and in direct contact with the poly(meth)acrylate layer. The hydrolytically resistant layer is disposed on and in direct contact with the epoxide and is the reaction product of an isocyanate component and an isocyanate-reactive component reacted in the presence of a curing agent. The isocyanate-reactive component includes a polydiene polyol and the curing agent crosslinks the carbon-carbon double bonds of the polydiene polyol.
    Type: Application
    Filed: January 13, 2017
    Publication date: January 24, 2019
    Inventors: Jeffrey A. DODGE, Andre KAMM, Charles E. JONES Jr., Karl R. GUST
  • Publication number: 20190024840
    Abstract: A composite article is formed by disposing a poly(meth)acrylate layer, formed as the reaction product of at least one acrylate that is polymerized in the presence of an organoborane initiator, on and in direct contact with a low surface energy polymer layer, disposing an epoxide layer on and in direct contact with said poly(meth)acrylate layer, and disposing a hydrolytically resistant layer on and in direct contact with said epoxide layer. The hydrolytically resistant layer is a hydrolytically resistant polyurethane elastomer that is the reaction product of an aliphatic isocyanate component and an isocyanate-reactive component that retains at least 90% of its initial tensile strength after submersion in standardized seawater for 24 weeks. The isocyanate-reactive component is a hydroxyl-functional polymer having an average hydroxy functionality ranging from 2 to 3, wherein the hydroxyl-functional polymer is a dimer diol, a trimer triol, or a combination thereof.
    Type: Application
    Filed: January 13, 2017
    Publication date: January 24, 2019
    Inventor: Jeffrey A. Dodge
  • Publication number: 20190017647
    Abstract: A composite article has increased pull-off strength and includes a first layer including a low surface energy polymer, a poly(meth)acrylate layer, and an epoxide layer. The poly(meth)acrylate layer is disposed on and in direct contact with the first layer. Moreover, the poly(meth)acrylate layer includes a poly(meth)acrylate that includes the reaction product of at least one (meth)acrylate that is polymerized in the presence of an organoborane initiator. The epoxide layer is disposed on and in direct contact with the poly(meth)acrylate layer. The epoxide layer includes an epoxide. The composite article has a pull-off strength of greater than zero pli measured using ASTM D4541.
    Type: Application
    Filed: January 13, 2017
    Publication date: January 17, 2019
    Inventor: Jeffrey A. Dodge
  • Patent number: 7501441
    Abstract: The present invention is a method for treating uterine fibroid disease using a compound of formula I wherein R1 is —H, —OH, —O(C1-C4 alkyl), —OCOC6H5, —OCO(C1-C6 alkyl), or —OSO2(C4-C6 alkyl); R2 is —H, —OH, —O(C1-C4 alkyl), —OCOC6H5, —OCO(C1-C6 alkyl) or —OSO2(C4-C6 alkyl); n is 2 or 3; and R3 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, or 1-hexamethyleneimino; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 20, 1994
    Date of Patent: March 10, 2009
    Assignee: Eli Lilly and Company
    Inventors: Henry U. Bryant, George J. Cullinan, Jeffrey A. Dodge, Kennan J. Fahey, Charles D. Jones, Charles W. Lugar, Brian S. Muehl
  • Publication number: 20070111988
    Abstract: The present invention relates to a selective estrogen receptor modulators of formula I (I); or a pharmaceutical acid addition salt thereof; and of formula II (II); or a pharmaceutical salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
    Type: Application
    Filed: January 18, 2005
    Publication date: May 17, 2007
    Applicant: ELI LILLY AND COMPANY
    Inventors: Robert Dally, Jeffrey Dodge, Conrad Hummel, Scott Jones, Timothy Shepherd, Owen Wallace, Wayne Weber
  • Publication number: 20070066595
    Abstract: The present invention relates to a selective estrogen receptor modulator of formula I: or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and uterine leiomyoma.
    Type: Application
    Filed: January 18, 2005
    Publication date: March 22, 2007
    Inventors: Jeffrey Dodge, Scott Frank, Conrad Hummel
  • Publication number: 20070054956
    Abstract: The present invention provides a compound of the formula (I) wherein R is —H, or —C1-C4 alkyl; R1 is —H, —OH, —O(C1-C4 alkyl), —SO2(C1-C4 alkyl), or halo; X is —O—, —CH2—, or —C(O)—; X1 is —O— or —NR2—; R2 is —H or —CH3; Y is —S—, —CH2CH2—, or —HC?CH—; m is 0, 1, 2, or 3; and n is 0 or 1; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions thereof; and methods for inhibiting a disease associated with an aberrant physiological response to endogenous estrogen.
    Type: Application
    Filed: May 27, 2004
    Publication date: March 8, 2007
    Inventors: Jeffrey Dodge, Norman Hughes
  • Publication number: 20060183736
    Abstract: The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
    Type: Application
    Filed: July 16, 2003
    Publication date: August 17, 2006
    Inventors: Robert Dally, Jeffrey Dodge, Scott Frank, Scott Jones, Timothy Shepherd, Owen Wallace, Kin Fong, Conrad Hummel, George Lewis
  • Publication number: 20050143318
    Abstract: What is disclosed are growth hormone secretagogues, and their uses, of formula (I) wherein R1 is C6H5CH2OCH2—, C6H5(CH2)3— or indol-3-ylmethyl; Y is pyrrolidin-1-yl, 4-C1-C6 alkylpiperidin-1-yl or NR2R2; R2 are each independently a C1 to C6 alkyl; R3 is 2-napthyl or phenyl para-substituted by W; W is H, F, CF3, C1-C6 alkoxy or phenyl; and R4 is H or CH3, or a pharmaceutically acceptable salt or solvate thereof.
    Type: Application
    Filed: September 2, 2004
    Publication date: June 30, 2005
    Inventors: Jeffrey Dodge, Charles Lugar
  • Publication number: 20040167080
    Abstract: A compound of the formula 1
    Type: Application
    Filed: February 12, 2004
    Publication date: August 26, 2004
    Inventors: Jeffrey A. Dodge, Charles A. Frolik, Terry D. Lindstrom, Charles W. Lugar, Gilbert S. Staten
  • Patent number: 6723739
    Abstract: A compound of the formula or a pharmaceutically acceptable salt or solvate thereof. Also provided by the invention are methods of use of the above compounds, and processes for the preparation thereof.
    Type: Grant
    Filed: March 15, 1995
    Date of Patent: April 20, 2004
    Assignee: Eli Lilly and Company
    Inventors: Jeffrey A. Dodge, Charles A. Frolik, Terry D. Lindstrom, Charles W. Lugar, III
  • Patent number: 6703407
    Abstract: The present invention provides novel, reduced benzothiophenes of formula I wherein R is —H, —OH, —O(C1-C4 alkyl), —O—CO—(C1-C6 alkyl), —O—CO—Ar in which Ar is optionally substituted phenyl, or —O—SO2—(C4-C6 alkyl); R1 is —H, —OH, —O(C1-C4 alkyl), —O—CO—(C1-C6 alkyl), —O—CO—Ar in which Ar is optionally substituted phenyl, —O—SO2—(C4-C6 alkyl) chloro or bromo; n is 2 or 3; and R2 and R3 each are independently C1-C4 alkyl, or combine to form 1-piperidinyl, 1-pyrrolidino, methyl-1-pyrrolidino, dimethyl-1-pyrrolidino, 4-morpholino or 1-hexamethyleneimino; or a pharmaceutically acceptable salt thereof. Further provided are methods for alleviating the symptoms of post-menopausal syndrome, and inhibiting endometriosis, uterine fibrosis, and aortal smooth muscle cell proliferation.
    Type: Grant
    Filed: September 20, 1994
    Date of Patent: March 9, 2004
    Assignee: Eli Lilly and Company
    Inventors: Henry U. Bryant, George J. Cullinan, Jeffrey A. Dodge, Kennan J. Fahey, Charles D. Jones
  • Patent number: 6608090
    Abstract: The instant invention provides novel benzothiophene compounds for use in treating skeletal diseases.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: August 19, 2003
    Assignee: Eli Lilly and Company
    Inventors: Michelle L. Bourgeois, Jeffrey A. Dodge, Charles D. Jones
  • Patent number: 6479517
    Abstract: This invention relates to the fields of pharmaceutical and organic chemistry and provides novel phosphorous-containing benzothiophene compounds which are useful for the treatment of the various medical indications associated with post-menopausal syndrome, as well as estrogen dependent diseases including cancer of the breast, uterus and cervix. The present invention further relates to intermediate compounds and processes useful for preparing the pharmaceutically active compounds of the present invention, and pharmaceutical compositions.
    Type: Grant
    Filed: February 28, 1995
    Date of Patent: November 12, 2002
    Assignee: Eli Lilly and Company
    Inventors: Henry U. Bryant, Jeffrey A. Dodge, Jeffrey S. Nissen
  • Patent number: 6444688
    Abstract: The instant invention provides compounds of formula I wherein R1 is OH, O—C(O)—(C1-C6 alkyl), O—C(O)—O(C1-C6 alkyl), O—C(O)—Ar, or O—C(O)—O—Ar; R2 is H, OH, O(C1-C6 alkyl), O—C(O)—(C1-C6 alkyl), O—C(O)—O(C1-C6 alkyl), O—C(O)—Ar, O—C(O)—O—Ar, O—SO2—(C4-C6 alkyl), chloro, fluoro, or bromo; V is S, O, or CH2CH2; W is CHOH, C(O), or CH2; X is (CH2)n; R3 and R4 each, independently, are H, C1-C6 alkyl, C(O)—(C1-C6 alkyl), C(O)—NH—(C1-C6 alkyl), C(O)—Ar, or together with the nitrogen to which they are attached form a 5- or 6-membered imide or cyclic amide; n is 1, 2, or 3; and Ar is optionally substituted phenyl; povided that at least one of R3 and R4 contains a carbonyl functional group, and their use in the treatment of estrogen deficiency pathologies.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 3, 2002
    Assignee: Eli Lilly and Company
    Inventors: Jeffrey A. Dodge, Charles D. Jones, Kristin Marron, James P. Sluka, Mark G. Stocksdale
  • Patent number: 6437137
    Abstract: The invention is a process for preparing a compound of formula Ia comprising reducing the compound of formula IIId wherein R3 is 1-piperidinyl, 1-pyrrolidinyl, dimethylamino, diethylamino or 1-hexamethyleneimino, R1a, R1b, R2a, R2b, and n are as defined in the specification, with a reducing agent in the presence of a solvent, heating to reflux.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: August 20, 2002
    Assignee: Eli Lilly and Company
    Inventors: Henry U. Bryant, George J. Cullinan, Jeffrey A. Dodge, Kennan J. Fahey, Charles D. Jones, Charles W. Lugar, Brian S. Muehl
  • Patent number: 6410564
    Abstract: The present invention provides a compound of formula I wherein R1 is —H, —OH, —O(C1-C4 alkyl) , —OCOC6H5, —OCO(C1-C6 alkyl), or —OSO2 (C4-C6 alkyl); R2 is —H, —OH, —O(C1-C4 alkyl), —OCOC6H5, —OCO(C1-C6 alkyl) or —OSO2 (C4-C6 alkyl); n is 2 or 3; and R3 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, or 1-hexamethyleneimino; or a pharmaceutically acceptable salt thereof. Compounds of formula I are useful in treating osteoporosis, cardiovascular related pathological conditions, and estrogen-dependent cancer.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: June 25, 2002
    Assignee: Eli Lilly and Company
    Inventors: Henry U. Bryant, George J. Cullinan, Jeffrey A. Dodge, Kennan J. Fahey, Charles D. Jones, Charles W. Lugar, Brian S. Muehl
  • Patent number: 6407243
    Abstract: The present invention provides novel compound of the formula: wherein Ra is —OH or —O—(C1-C4 alkyl); R1a is —OH or —O—(C1-C4 alkyl); n is 2 or 3; R2 and R3 are each independently: —C1-C4 alkyl, or combine to form 1-piperidinyl, 1-pyrrolidinyl, 1-pyrrolidinyl substituted with one or two methyl groups, 4-morpholino or 1-hexamethyleneimino; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 10, 1995
    Date of Patent: June 18, 2002
    Assignee: Eli Lilly and Company
    Inventors: Henry U. Bryant, George J. Cullinan, Jeffrey A. Dodge, Kennan J. Fahey, Charles D. Jones
  • Patent number: 6407201
    Abstract: The present invention provides a plasticizer compound having the general formula: in which n=1 to 3, R represents a C2-C8 straight or branched aliphatic hydrocarbon chain or C6-C10 aromatic or cycloaliphatic group, and R′ and R″ are each independently a branched oxyalkylene chain represented by the chemical formula C8H16O and by the chemical structures: The present invention is also directed to a coverstock formulation comprising the above-plasticizer compound.
    Type: Grant
    Filed: August 21, 2000
    Date of Patent: June 18, 2002
    Assignee: Bayer Corporation
    Inventors: Ronald P. Taylor, Jeffrey A. Dodge, Hartmut Nefzger